*Based on commercial patients, early access patients, and clinical trial participants through December 2019.
†Includes clinical trial patients.
‡Clinical studies of SPINRAZA did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger patients.
§Based on commercial patients in the US (including Puerto Rico) through December 2019.
SPINRAZA is the treatment that’s been studied in the longest clinical trial program in SMA to date.3
The most common side effects of SPINRAZA include lower respiratory infection, pyrexia, constipation, headache, vomiting, back pain, and post-lumbar puncture syndrome. These are not all of the possible side effects of SPINRAZA.
Individual results may vary based on several factors, including severity of disease, initiation of treatment, and duration of therapy.
“When you’re living with SMA, it really is about the small victories.”